184 related articles for article (PubMed ID: 22958421)
1. Macrolides decrease the minimal inhibitory concentration of anti-pseudomonal agents against Pseudomonas aeruginosa from cystic fibrosis patients in biofilm.
Lutz L; Pereira DC; Paiva RM; Zavascki AP; Barth AL
BMC Microbiol; 2012 Sep; 12():196. PubMed ID: 22958421
[TBL] [Abstract][Full Text] [Related]
2. In vitro prevention of Pseudomonas aeruginosa early biofilm formation with antibiotics used in cystic fibrosis patients.
Fernández-Olmos A; García-Castillo M; Maiz L; Lamas A; Baquero F; Cantón R
Int J Antimicrob Agents; 2012 Aug; 40(2):173-6. PubMed ID: 22727530
[TBL] [Abstract][Full Text] [Related]
3. Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.
Díez-Aguilar M; Morosini MI; Köksal E; Oliver A; Ekkelenkamp M; Cantón R
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084746
[No Abstract] [Full Text] [Related]
4. Advances toward the elucidation of hypertonic saline effects on Pseudomonas aeruginosa from cystic fibrosis patients.
Michon AL; Jumas-Bilak E; Chiron R; Lamy B; Marchandin H
PLoS One; 2014; 9(2):e90164. PubMed ID: 24587256
[TBL] [Abstract][Full Text] [Related]
5. Activity of Antibiotics against Pseudomonas aeruginosa in an
Diaz Iglesias Y; Van Bambeke F
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015047
[No Abstract] [Full Text] [Related]
6. A Low-Molecular-Weight Alginate Oligosaccharide Disrupts Pseudomonal Microcolony Formation and Enhances Antibiotic Effectiveness.
Pritchard MF; Powell LC; Jack AA; Powell K; Beck K; Florance H; Forton J; Rye PD; Dessen A; Hill KE; Thomas DW
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630204
[TBL] [Abstract][Full Text] [Related]
7. In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells.
Yu Q; Griffin EF; Moreau-Marquis S; Schwartzman JD; Stanton BA; O'Toole GA
J Antimicrob Chemother; 2012 Nov; 67(11):2673-81. PubMed ID: 22843834
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model.
Tré-Hardy M; Nagant C; El Manssouri N; Vanderbist F; Traore H; Vaneechoutte M; Dehaye JP
Antimicrob Agents Chemother; 2010 Oct; 54(10):4409-15. PubMed ID: 20696878
[TBL] [Abstract][Full Text] [Related]
9. Does ivacaftor interfere with the antimicrobial activity of commonly used antibiotics against Pseudomonas aeruginosa?-Results of an in vitro study.
Millar BC; Rendall JC; Downey DG; Moore JE
J Clin Pharm Ther; 2018 Dec; 43(6):836-843. PubMed ID: 29959786
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions.
McCaughey G; McKevitt M; Elborn JS; Tunney MM
J Cyst Fibros; 2012 May; 11(3):163-72. PubMed ID: 22138067
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of clarithromycin in combination with other antimicrobial agents against biofilm-forming Pseudomonas aeruginosa strains.
Kádár B; Szász M; Kristóf K; Pesti N; Krizsán G; Szentandrássy J; Rókusz L; Nagy K; Szabó D
Acta Microbiol Immunol Hung; 2010 Sep; 57(3):235-45. PubMed ID: 20870595
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria.
Strateva T; Petrova G; Mitov I
J Chemother; 2010 Dec; 22(6):378-83. PubMed ID: 21303744
[TBL] [Abstract][Full Text] [Related]
13. Characterization by phenotypic and genotypic methods of metallo-β-lactamase-producing Pseudomonas aeruginosa isolated from patients with cystic fibrosis.
Li Y; Zhang X; Wang C; Hu Y; Niu X; Pei D; He Z; Bi Y
Mol Med Rep; 2015 Jan; 11(1):494-8. PubMed ID: 25323940
[TBL] [Abstract][Full Text] [Related]
14. Airway biofilms: implications for pathogenesis and therapy of respiratory tract infections.
Kobayashi H
Treat Respir Med; 2005; 4(4):241-53. PubMed ID: 16086598
[TBL] [Abstract][Full Text] [Related]
15. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.
Moskowitz SM; Foster JM; Emerson J; Burns JL
J Clin Microbiol; 2004 May; 42(5):1915-22. PubMed ID: 15131149
[TBL] [Abstract][Full Text] [Related]
16. Effect of pH on the antimicrobial susceptibility of planktonic and biofilm-grown clinical Pseudomonas aeruginosa isolates.
Moriarty TF; Elborn JS; Tunney MM
Br J Biomed Sci; 2007; 64(3):101-4. PubMed ID: 17910277
[TBL] [Abstract][Full Text] [Related]
17. Biofilm production using distinct media and antimicrobial susceptibility profile of Pseudomonas aeruginosa.
Perez LR; Barth AL
Braz J Infect Dis; 2011; 15(4):301-4. PubMed ID: 21860998
[TBL] [Abstract][Full Text] [Related]
18. Effect of iron chelation on anti-pseudomonal activity of doxycycline.
Faure ME; Cilibrizzi A; Abbate V; Bruce KD; Hider RC
Int J Antimicrob Agents; 2021 Dec; 58(6):106438. PubMed ID: 34547423
[TBL] [Abstract][Full Text] [Related]
19. Use of artificial sputum medium to test antibiotic efficacy against Pseudomonas aeruginosa in conditions more relevant to the cystic fibrosis lung.
Kirchner S; Fothergill JL; Wright EA; James CE; Mowat E; Winstanley C
J Vis Exp; 2012 Jun; (64):e3857. PubMed ID: 22711026
[TBL] [Abstract][Full Text] [Related]
20. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Smith S; Waters V; Jahnke N; Ratjen F
Cochrane Database Syst Rev; 2020 Jun; 6(6):CD009528. PubMed ID: 32520436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
